A New 3D Virtual Reality-based Upper Limb Training to Improve Dexterity in Parkinson's Disease

Sponsor
Luzerner Kantonsspital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05965661
Collaborator
(none)
20
1
2
29.4
0.7

Study Details

Study Description

Brief Summary

We investigate the impact of a 4-week virtual reality-based upper limb training in Parkinson's disease. The benefits on dexterity of this training program will be evaluated.

For these purposes, a randomised, two arm, single assessor blind, parallel design with a monocentric, study setup will be performed.

Condition or Disease Intervention/Treatment Phase
  • Other: virtual reality upper limb hand training
  • Other: virtual reality control training
N/A

Detailed Description

Patients with Parkinson's disease (PD) suffer from significantly decreased coordination and have difficulties with precise hand/finger movements during the performance of both basic activities of daily living (ADL), such as dressing, grooming as well as higher ADL, such as cooking, shopping and regular medication intake. These difficulties further add to the burden of the disease, leading to reduced quality of life (QoL). A relatively new, but rapidly growing aspect of training in PD neurorehabilitation offers virtual reality (VR). We explore the effects of a VR-based upper limb hand training compared to a VR control training, which is less specific for dexterity. Moreover, we examine the effetcs of the trainings on upper limb related ADL, and therefore the impact on QoL in patients with PD.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized pilot studyRandomized pilot study
Masking:
Single (Outcomes Assessor)
Masking Description:
VR upper limb hand training or VR control training
Primary Purpose:
Treatment
Official Title:
A New 3D Virtual Reality-based Upper Limb Training to Improve Dexterity in Parkinson's Disease: a Randomized Pilot Study
Actual Study Start Date :
Jul 19, 2023
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Other: Virtual reality upper limb hand training

The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.

Other: virtual reality upper limb hand training
The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.

Other: Virtual reality control training

The PD patients randomized in the control group will receive virtual reality control training.

Other: virtual reality control training
The PD patients randomized in the control group will receive virtual reality control training.

Outcome Measures

Primary Outcome Measures

  1. fine finger movements [4 weeks]

    Coin rotation task (CRT): The CRT measures fine coordinated finger movements and is a suitable and valid dexterity test in patients with PD. The seconds for 20 halfturns will be measured.

Secondary Outcome Measures

  1. hand dexterity [4 weeks]

    Nine Hole Peg test (9-HPT): The 9-HPT is a standardized, well established, and reliable measure of hand dexterity in patients with PD. seconds will be measured.

  2. grip strenght [4 weeks]

    The handheld JAMAR dynamometer measures the grip strength. kg will be measured.

  3. motor function [4 weeks]

    MDS-Sponsored Revision of the Unified Parkinson Disease Rating Scale (MDS-UPDRS III): It evaluates motor aspects of Parkinson's disease

  4. self-reported dexterity related problems in daily living [4 weeks]

    Dexterity Questionnaire 24 (DextQ-24): This questionnaire is a standardized patient self-rated outcome measure (PROM) for evaluating dexterity related ADL in PD. score range 24-96, higher scores mean more dexterity problems.

  5. self-reported problems in quality of life [4 weeks]

    Parkinson's Disease Questionnaire (PDQ-39): This questionnaire is a standardized patient self-rated outcome measure (PROM) for evaluating QOL in PD. range 0-156, higher values mean more problems.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with confirmed PD, according to UK Brain bank Criteria

  • Hoehn & Yahr Stadium I to IV

  • Age 40 to 99 years

  • written and signed informed consent

  • self-reported dexterous difficulties

Exclusion Criteria:
  • MoCA <21/30

  • psychiatric disease

  • participation on other interventional trials

  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.

  • severe visual impairment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Luzerner Kantonsspital Lucerne Switzerland 6000

Sponsors and Collaborators

  • Luzerner Kantonsspital

Investigators

  • Principal Investigator: Tim Vanbellingen, Prof, Luzerner Kantonsspital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Luzerner Kantonsspital
ClinicalTrials.gov Identifier:
NCT05965661
Other Study ID Numbers:
  • 2022-01545
First Posted:
Jul 28, 2023
Last Update Posted:
Jul 28, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Luzerner Kantonsspital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 28, 2023